All products and services are For Research Use Only and CANNOT be used in the treatment or diagnosis of disease.
CAT | Product Name | Target Species | TCR Clone | Host Species | Epitope | Allele | Vector Type | Inquiry & Datasheet |
TCR-YC1284 | Human anti-UL49 T cell receptor (2), pCDTCR1 | HHV2 | 2 | Human | RPRGEVRFL | HLA-B*07:02 | Lentiviral vector | |
TCR-YC1285 | Human anti-UL49 T cell receptor (10), pCDTCR1 | HHV2 | 10 | Human | RPRGEVRFL | HLA-B*07:02 | Lentiviral vector | |
TCR-YC1286 | Human anti-UL49 T cell receptor (12), pCDTCR1 | HHV2 | 12 | Human | RPRGEVRFL | HLA-B*07:02 | Lentiviral vector | |
TCR-YC1287 | Human anti-UL49 T cell receptor (16), pCDTCR1 | HHV2 | 16 | Human | RPRGEVRFL | HLA-B*07:02 | Lentiviral vector | |
TCR-YC1288 | Human anti-UL49 T cell receptor (23), pCDTCR1 | HHV2 | 23 | Human | RPRGEVRFL | HLA-B*07:02 | Lentiviral vector | |
TCR-YC1289 | Human anti-UL49 T cell receptor (37), pCDTCR1 | HHV2 | 37 | Human | RPRGEVRFL | HLA-B*07:02 | Lentiviral vector | |
TCR-YC1290 | Human anti-UL49 T cell receptor (45), pCDTCR1 | HHV2 | 45 | Human | RPRGEVRFL | HLA-B*07:02 | Lentiviral vector | |
TCR-YC1291 | Human anti-UL49 T cell receptor (1B1), pCDTCR1 | HHV2 | 1B1 | Human | RPRGEVRFL | HLA-B*07:02 | Lentiviral vector | |
TCR-YC1292 | Human anti-UL49 T cell receptor (2F1), pCDTCR1 | HHV2 | 2F1 | Human | RPRGEVRFL | HLA-B*07:02 | Lentiviral vector | |
TCR-YC1293 | Human anti-UL49 T cell receptor (cl6), pCDTCR1 | HHV2 | cl6 | Human | RPRGEVRFL | HLA-B*07:02 | Lentiviral vector | |
TCR-YC1294 | Human anti-UL49 T cell receptor (H21), pCDTCR1 | HHV2 | H21 | Human | RPRGEVRFL | HLA-B*07:02 | Lentiviral vector | |
TCR-YC1295 | Human anti-UL49 T cell receptor (H24), pCDTCR1 | HHV2 | H24 | Human | RPRGEVRFL | HLA-B*07:02 | Lentiviral vector | |
TCR-YC1296 | Human anti-UL49 T cell receptor (L23), pCDTCR1 | HHV2 | L23 | Human | RPRGEVRFL | HLA-B*07:02 | Lentiviral vector | |
TCR-YC1297 | Human anti-UL49 T cell receptor (L4), pCDTCR1 | HHV2 | L4 | Human | RPRGEVRFL | HLA-B*07:02 | Lentiviral vector | |
TCR-YC1298 | Human anti-UL49 T cell receptor (L40), pCDTCR1 | HHV2 | L40 | Human | RPRGEVRFL | HLA-B*07:02 | Lentiviral vector | |
TCR-YC1299 | Human anti-UL49 T cell receptor (V6-12), pCDTCR1 | HHV2 | V6-12 | Human | RPRGEVRFL | HLA-B*07:02 | Lentiviral vector | |
TCR-YC1300 | Human anti-UL49 T cell receptor (V6-7), pCDTCR1 | HHV2 | V6-7 | Human | RPRGEVRFL | HLA-B*07:02 | Lentiviral vector | |
TCR-YC1301 | Human anti-UL49 T cell receptor (W19), pCDTCR1 | HHV2 | W19 | Human | RPRGEVRFL | HLA-B*07:02 | Lentiviral vector | |
TCR-YC1302 | Human anti-UL49 T cell receptor (W21), pCDTCR1 | HHV2 | W21 | Human | RPRGEVRFL | HLA-B*07:02 | Lentiviral vector |
The latest newsletter to introduce the latest breaking information, our site updates, field and other scientific news, important events, and insights from industry leaders
LEARN MORE NEWSLETTERCellRapeutics™ In Vivo Cell Engineering: One-stop in vivo T/B/NK cell and macrophage engineering services covering vectors construction to function verification.
LEARN MORE SOLUTIONSilence™ CAR-T Cell: A novel platform to enhance CAR-T cell immunotherapy by combining RNAi technology to suppress genes that may impede CAR functionality.
LEARN MORE NOVEL TECHNOLOGYCanine CAR-T Therapy Development: From early target discovery, CAR design and construction, cell culture, and transfection, to in vitro and in vivo function validation.
LEARN MORE SOLUTION